Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.16 USD | -2.58% | 0.00% | +5.05% |
Sales 2024 * | 346M 252M | Sales 2025 * | 356M 260M | Capitalization | 550M 401M |
---|---|---|---|---|---|
Net income 2024 * | 2M 1.46M | Net income 2025 * | 13M 9.48M | EV / Sales 2024 * | 1.59 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 1.54 x |
P/E ratio 2024 * |
190
x | P/E ratio 2025 * |
53.2
x | Employees | 725 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 54.52% |
Latest transcript on Knight Therapeutics Inc.
1 day | -2.58% | ||
Current month | -4.83% | ||
1 month | -5.67% | ||
3 months | +7.19% | ||
6 months | +8.00% | ||
Current year | +5.05% |
Managers | Title | Age | Since |
---|---|---|---|
Samira Sakhia
CEO | Chief Executive Officer | 55 | 13-10-31 |
Jonathan Goodman
FOU | Founder | 56 | 13-10-31 |
Arvind Utchanah
DFI | Director of Finance/CFO | - | 16-06-19 |
Members of the board | Title | Age | Since |
---|---|---|---|
James Gale
BRD | Director/Board Member | 74 | 14-01-05 |
Jonathan Goodman
FOU | Founder | 56 | 13-10-31 |
Robert Lande
BRD | Director/Board Member | 61 | 12-12-31 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+15.72% | 77.46B | |
+13.65% | 8.94B | |
-24.30% | 4.28B | |
+12.79% | 4.18B | |
+10.97% | 2.23B | |
-30.57% | 2.06B | |
+8.99% | 1.97B | |
-45.76% | 1.69B | |
-0.50% | 1.64B |
- Stock Market
- Equities
- GUD Stock
- KHTRF Stock